Abeona Therapeutics Inc vs Newegg Commerce Inc — how do they compare? Abeona Therapeutics Inc trades at $7.51 (market cap $421.19M), while Newegg Commerce Inc trades at $19.64 (market cap $398.29M). The key difference: Abeona Therapeutics Inc and Newegg Commerce Inc are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | NEGG | |
|---|---|---|
Market Cap | $421.19M | $398.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $128.09 |
52-Week Low | $4.17 | $12.87 |
Enterprise Value | $276.10M | $397.09M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
NEGG trades at $18.99, up 3.32% today, with a bullish technical signal from moving averages. Recent earnings beat expectations, showing improved profitability with a net income margin of 0.39% in 2025, up from negative margins in prior years. The company maintains a low P/S ratio of 0.28, but a high P/E of 73.16 reflects growth expectations. News highlights include AI shopping features and product launches, indicating innovation efforts.
Outlook: NEGG shows operational improvement with narrowing losses, but negative operating cash flow and high valuation multiples pose risks. The sole analyst coverage is bullish, yet investor caution is warranted due to competitive pressures and reliance on tech spending cycles. Upside depends on sustained revenue growth and margin expansion.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →